Human chorionic gonadotrophin contributes to the bioactivity of Pergonal

Rodgers, M.; Mitchell, R. M.; Lambert, Ann; Peers, N.; Robertson, W. R.

doi:10.1111/j.1365-2265.1992.tb01488.x

Cited by 30 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HMG preparations contain similar (1:1 ratio) FSH and LH activity, as required by regulatory agencies (286,287). The most significant improvements of HMG preparations over the years involved the introduction of 1) purified urinary FSH (with only minute amounts of LH), 2) highly purified urinary FSH (obtained through an affinity extraction procedure, removing virtually all of the contaminating proteins) (288), and 3) human recombinant FSH preparations (113, 289 -291).…”

Section: Hormone Preparation-related Factorsmentioning

confidence: 99%

Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences*

Fauser¹,

Heusden²

1997

Endocrine Reviews

223

165

View full text Add to dashboard Cite

Section: Hormone Preparation-related Factorsmentioning

confidence: 99%

Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences*

Fauser¹,

Heusden²

1997

Endocrine Reviews

223

165

View full text Add to dashboard Cite

“…As the primary aim was to mimic ovarian stimulation conditions in vivo, in vitro-grown follicles at the early antral stage (Day 6) were exposed to recombinant gonadotropins at an FSH/LH ratio that mimics a classical menotropin-induced stimulation protocol [37]. It was decided to use hCG as LH-bioactive component as this molecule is generally used to spike for LH bioactivity to the requested 75 IU per ampoule on a menotropin preparation [38].…”

Section: Discussionmentioning

confidence: 99%

Exposing cultured mouse ovarian follicles under increased gonadotropin tonus to aromatizable androgens influences the steroid balance and reduces oocyte meiotic capacity

Romero

Smitz

2010

Endocr

View full text Add to dashboard Cite

Acquisition of oocyte developmental competence relies on the well-controlled events accompanying antral follicular development. Elevated basal androgen levels, as in PCOS, potentially affect oocyte quality. Current experiments in an in vitro follicle bioassay studied dose-effects of androstenedione and testosterone on FSH and hCG stimulated antral follicle growth and meiotic maturation. The addition of either androgens altered follicle's endogenous production of androstenedione, testosterone, estradiol, and progesterone and affected the oocyte's capacity to resume meiosis. Exposure to 200 nM androstenedione induced an increased production of testosterone and estradiol. Exposure to a concentration of ≥200 nM testosterone induced elevated levels of estradiol and progesterone. Significant dose-dependent negative effects on polar body extrusion were seen at concentrations of ≥200 nM of either androgen. In addition, chromosome displacement on the metaphase plate was observed in oocytes obtained from androstenedione-treated follicles. Follicles exposed to a combination of 25 mIU/ml FSH and 3 mIU/ml hCG and elevated aromatizable androgens altered the steroid production profile, affected the follicular development and impaired oocyte meiotic competence.

show abstract

“…This has been confirmed in gene expression studies where there was consistently lower expression of the LH/hCG receptor gene in granulosa cells from women undergoing controlled ovarian hyperstimulation who were treated with hMG compared with those treated with r-hFSH [ 32 ]. Thus, the high levels of hCG contained in hMG, together with its longer half-life, may lead to an undesirable accumulation of LH-like bioactivity with possible premature luteinisation and reduced fertilisation rates [ 35 ] or to a reduced response as a result of LH/hCG receptor desensitisation.…”

Section: Reviewmentioning

confidence: 99%

A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology

Ezcurra¹,

Humaıdan

2014

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Gonadotropins extracted from the urine of post-menopausal women have traditionally been used to stimulate folliculogenesis in the treatment of infertility and in assisted reproductive technology (ART). Products, such as human menopausal gonadotropin (hMG), consist not only of a mixture of the hormones, follicle-stimulating hormone (FSH), luteinising hormone (LH) and human chorionic gonadotropin (hCG), but also other biologically active contaminants, such as growth factors, binding proteins and prion proteins. The actual amount of molecular LH in hMG preparations varies considerably due to the purification process, thus hCG, mimicking LH action, is added to standardise the product. However, unlike LH, hCG plays a different role during the natural human menstrual cycle. It is secreted by the embryo and placenta, and its main role is to support implantation and pregnancy. More recently, recombinant gonadotropins (r-hFSH and r-hLH) have become available for ART therapies. Recombinant LH contains only LH molecules. In the field of reproduction there has been controversy in recent years over whether r-hLH or hCG should be used for ART. This review examines the existing evidence for molecular and functional differences between LH and hCG and assesses the clinical implications of hCG-supplemented urinary therapy compared with recombinant therapies used for ART.

show abstract

Human chorionic gonadotrophin contributes to the bioactivity of Pergonal

Cited by 30 publications

References 29 publications

Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences*

Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences*

Exposing cultured mouse ovarian follicles under increased gonadotropin tonus to aromatizable androgens influences the steroid balance and reduces oocyte meiotic capacity

A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology

Contact Info

Product

Resources

About